丁苯酞联合神经节苷脂在血管性痴呆的临床疗效

Clinical Efficacy of Butylphthalide Combined with Ganglioside on Vascular Dementia

目的探讨丁苯酞联合神经节苷脂治疗血管性痴呆的临床效果。方法选取2017年3月至2018年11月广东医科大学附属医院78例血管性痴呆患者作为研究对象,将其随机分为对照组和研究组,每组39例。对照组患者仅采用丁苯酞进行治疗,研究组在此基础上联合应用神经节苷脂,比较两组患者的治疗效果,治疗效果主要从MMSE、ADL、Blessed-Roth评分,以及不良反应发生情况和治疗有效率进行比较。结果治疗前,两组患者的MMSE、ADL、Blessed-Roth评分相比较,差异无统计学意义(P<0.05),治疗后研究组患者的MMSE、ADL评分显著高于对照组,Blessed-Roth评分显著低于对照组,差异有统计学意义(P<0.05)。研究组的不良反应发生率为12.82%(5/39),对照组为28.21%(11/39),差异无统计学意义(P>0.05)。研究组的治疗有效率为89.74%,对照组为53.85%,研究组高于对照组,差异有统计学意义(P<0.05)。结论丁苯酞联合神经节苷脂治疗血管性痴呆疗效显著。

Objective To explore the clinical efficacy of butylphthalide combined with ganglioside on vascular dementia.Methods A total of 78 patients with vascular dementia in the Affiliated Hospital of Guangdong Medical University from March 2017 to November 2018 were selected as research objects.They were randomly divided into control group and study group,with 39 cases in each group.Patients in the control group were treated with butylphthalide,while those in the study group were given butylphthalide combined with ganglioside.Clinical effects including MMSE,ADL,Blessed-Roth scores,occurrence of adverse reactions and effective rate of the 2 groups were compared.Results There was no significant difference in the MMSE,ADL and Blessed-Roth scores of the 2 groups before the treatment(P<0.05).After the treatment,the MMSE score and ADL score of the study group were remarkably higher than those of the control group,and the Blessed-Roth score was much lower than the that of control group,with statistically significant difference(P<0.05).The incidence of adverse reactions in the study group was 12.82%(5/39)and that in the control group was 28.21%(11/39),with no statistically significant difference(P>0.05).The effective rates in the study group and the control group were 89.74%and 53.85%respectively.So it was higher in the study group than that in the control group,with statistically significant difference(P<0.05).Conclusion Butylphthalide combined with ganglioside has remarkable clinical efficacy on vascular dementia.